Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
Psychology Today18h
Therapists in California
In addition to neuropsychology Dr. Gaines also provides therapy for a variety of psychological issues. Dr. Dee Gaines is trained extensively in Neuropsychology and Clinical Psychology and is ...